Navigation Links
Karolinska Development and Uminova Invest Sign Co-operation Agreement
Date:1/14/2010

STOCKHOLM and UMEA, Sweden, January 14 /PRNewswire/ -- Karolinska Development AB and Uminova Invest AB have entered into a co-operation agreement that will enrich the flow of investment opportunities available to Karolinska Development and enable cost effective commercial development for Uminova Invest's portfolio companies. The agreement involves evaluation of potential investments; advise to existing portfolio companies as well as exit issues.

Uminova Invest is a regional private equity capital firm providing capital and competence to prospective growth companies and entrepreneurs with a connection to the Umea University or other educational and research activities in the county of Vasterbotten.

"Umea region excels having created a very strong cluster of life science innovations over the past years and this agreement offers us access to some very exciting commercial opportunities", says Conny Bogentoft, CEO of Karolinska Development.

"Over the past years we have had an ongoing exchange with Karolinska Development, this has now been formalized. This formal co-operation agreement provides further opportunities to create viable companies", says Jan Olsson, CEO of Uminova Invest.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first in class products. http://www.karolinskadevelopment.com

About Uminova Invest

Uminova Invest focuses on prospective growth companies and people with interesting ideas and an entrepreneur spirit at a stage when the addition of capital and competence is vital for the company's growth. The idea, product or service must be unique with a high market potential, and must have a connection to the Umea University or other educational and research activities in the county of Vasterbotten. http://www.uminovainvest.se

    For more information, please contact:

    Conny Bogentoft CEO Karolinska Development
    Tel: +46(0)706-88-61-43, e-mail:
    conny.bogentoft@karolinskadevelopment.com

    Jan Olsson CEO Uminova Invest
    Tel: +46(0)703-44-16-80, email: jan.olsson@uminovainvest.se

SOURCE Karolinska Development AB and Uminova Invest AB


'/>"/>
SOURCE Karolinska Development AB and Uminova Invest AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
2. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
3. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
4. Karolinska Development Closes Fully Subscribed New Share Issue
5. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Baltimore, Maryland (PRWEB) , ... ... ... firm, PathSensors, Inc., announced today that in a published evaluation of multiple ... (PNNL), a U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection ...
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 non-profit, ... is to advance global health and highlight the greater good of clinical trial participation ... trial volunteer. The vision of GGI is to serve as a philanthropic connector between ...
(Date:2/23/2017)... and SAN FRANCISCO , ... privately-held regenerative medicine company, and Beyond Type 1, a ... type 1 diabetes, today announced a grant from Beyond ... functional cure for type 1 and other insulin-requiring diabetes.  ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a neurotechnology ... for research and clinical applications. The terms of the transaction were not disclosed. ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):